CID1067700
Rab7 GTPase inhibitor / A specific competitive inhibitor of nucleotide binding to Rab7, an endosome-localized small GTPase.1 It interferes with the Rab7-RILP interaction, locking the GTPase in an inactive conformation.2 Impairs B cell class switching and plasma cell survival dampening, the pathogenic autoantibody response in lupus.3 Inhibits the Arf-like small GTPase Arl8b, blocking cellular egress of b-coronaviruses (SARS-CoV-2) which utilize a lysosomal exocytosis pathway.4
Biochemicals & reagents
314042-01-8
ML282
1) Agola et al. (2012), A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition; ACS Chem. Biol., 7 1095 2) Agola et al. (2015), Quantitative bead-based flow cytometry for assaying Rab7 GTPase interaction with the Rab-interacting lysomal protein (RILP) effector protein; Methods Mol. Biol., 1298 331 3) Lam et al. (2016), Small Molecule Inhibition of Rab7 Impairs B Cell Switching and Plasma Cell Survival To Dampen the Autoantibody response in Murine Lupus; J. Immunol.., 197 3792 4) Ghosh et al. (2020), ß-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway; Cell, 183 1520
-20°C
TARGET: GTPase; Lysosome -- PATHWAY: Autophagy -- RESEARCH AREA: Immunology; Cell death; Neuroscience -- DISEASE AREA: Infectious disease; IschemiaNeurodegeneration